Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Food Effect Study of Belzutifan in Healthy Volunteers
NCT03445169Phase 1Completed
- Sponsor
- Merck & Co.
- Start
- Feb 2018
- Primary completion
- May 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of belzutifan in renal cell carcinoma (RCC) and von Hippel–Lindau disease (VHL) (2 arms), sponsored by Merck & Co. Primary endpoint: Plasma Concentrations of belzutifan at 9 days. Started Feb 2018; status: completed.
02
Drugs
belzutifan
03
Conditions
renal cell carcinoma (RCC)von Hippel–Lindau disease (VHL)
Beyond the preview
Go deeper on NCT03445169.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03445169.